Amedisys, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a AMED research report →
Range $85 – $190
Price Chart
About the company
Amedisys, Inc. , along with its various subsidiaries, delivers a spectrum of healthcare solutions throughout the United States. Its operations are structured across four distinct divisions: Home Health, Hospice, Personal Care, and High Acuity Care.
- CEO
- Richard M. Ashworth
- IPO
- 1994
- Employees
- 19,000
- HQ
- Baton Rouge, LA, US
Get TickerSpark's AI analysis on AMED
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $3.32B
- P/E
- 76.51
- Fwd P/E
- 19.55
- PEG
- 2.33
- P/S
- 1.41
- P/B
- 2.91
- EV/EBITDA
- 42.68
- Div Yield
- 0.00%
- Gross Margin
- 43.34%
- Op Margin
- 4.03%
- Net Margin
- 1.84%
- ROE
- 3.93%
- ROIC
- 2.44%
Latest fiscal year · YoY change
- Revenue
- $2.35B+5.0%
- Gross Profit
- $1.02B+2.7%
- Op Income
- $94.54M
- Net Income
- $43.23M+543.5%
- EPS
- $1.32+540.0%
- OCF Growth
- +61.6%
- FCF Growth
- +72.2%
- 52W High
- $101.02
- 52W Low
- $82.15
- 50D MA
- $97.76
- 200D MA
- $93.41
- Beta
- 0.90
- RSI (14)
- 75
- Avg Volume
- 517.90K
Earnings call summaries
Pick a quarter — each call distilled into takeaways, results, and a bull vs bear read.
Amedisys topped $562 million of Q4 revenue and reiterated a 2023 guide that assumes strong demand, but management stressed labor, payer mix, and Contessa losses remain key execution challenges.· February 16, 2023
- Q4 GAAP revenue was $562 million with net income of $31.7 million, or $0.97 per diluted share.
- Full-year 2022 GAAP revenue was $2.22 billion and net income was $119 million, or $3.63 per diluted share.
- 2023 guidance calls for $2.244 billion to $2.274 billion of adjusted revenue, $230 million to $240 million of adjusted EBITDA, and $4.13 to $4.36 of adjusted EPS.
- Management said labor scarcity and Medicare Advantage contract economics are changing the business, with willingness to cancel or move away from underpaying contracts.
- Contessa is still a drag, with 2023 EBITDA losses expected to remain around the 2022 level, but management sees upside from new JV and palliative care deals.
Amedisys reported Q4 2022 GAAP net income of $31.7 million, or $0.97 per diluted share, on $562 million of revenue, up $3 million year over year. For full-year 2022, GAAP net income was $119 million, or $3.63 per diluted share, on $2.22 billion of revenue. On an adjusted basis, full-year 2022 revenue was $2.2 billion, up $25 million or 1%; adjusted EBIT was $262 million, down $38 million or 12.5%; adjusted EBITDA margin was 11.7%, down 190 basis points; and adjusted EPS was $5.01, down $0.94. In Q4 on an adjusted basis, revenue was $562 million, adjusted EBITDA was $60 million, adjusted EBITDA margin was 10.7%, and adjusted EPS was $1.16. Segment detail included home health revenue of $343 million, hospital revenue of $198 million, and hospice EBITDA of $44 million. Cash flow from operations was $41 million in Q4 and $133 million for the full year, with net leverage at 1.5x. For 2023, management guided to adjusted revenue of $2.244 billion to $2.274 billion, adjusted EBITDA of $230 million to $240 million, and adjusted EPS of $4.13 to $4.36. Management also said Contessa revenue would be nearly $50 million in 2023, while Contessa EBITDA losses were expected to be roughly flat versus 2022 at about a $30 million drag.
Paul Kusserow framed the quarter around a major shift in the industry: more consumer demand, more Medicare Advantage penetration, and a severe labor shortage that makes capacity the main constraint. He said Amedisys will focus on four priorities in 2023: people, growth, clinical optimization/automation, and Contessa. His tone was confident and assertive, especially on payer negotiations, saying the company will not be commoditized and may cancel contracts if rates do not reflect labor inflation and capacity realities.
Scott Ginn walked through the financial bridge and flagged several 2023 headwinds: about $45 million from higher labor costs and benefit enhancements, $23 million from incentive compensation, $14 million from mix shift away from episodic to per-visit, about $10 million from other items, and a $6 million EBITDA contribution lost from the personal care divestiture. He said clinical optimization should drive nearly $20 million in cost savings in 2023, with another step-up expected in 2024. He also noted operating cash flow of $133 million in 2022 and guided to roughly $210 million to $215 million in 2023, while maintaining net leverage at 1.5x and preserving dry powder for M&A.
Analysts focused on whether guidance was realistic given prior misses, the pace of Medicare Advantage contracting, labor tightness, hospice discharge stabilization, and Contessa’s slow ramp. Management said the 2023 plan is more conservative and that the business now has more predictable levers, including turnover reduction, better payer mix, and clinical optimization. On Contessa, they said losses should remain about flat near a $30 million EBITDA drag, but revenue can step up as new JV and palliative care relationships come online; they stopped short of giving a breakeven timeline. On labor, management said January was the best month for offers in company history, but they also acknowledged some markets are still constrained and that they are turning away some volume in select areas.
The company is seeing strong demand for home-based care, and management believes scarcity of labor and hospital discharge pressure will push more volume toward Amedisys over time. They also pointed to better recruiting trends, a strong M&A pipeline, and potential upside from new case-rate and palliative care arrangements. Management sounded increasingly confident that the business can gain pricing power if it uses its capacity selectively.
Labor remains a major constraint, with management acknowledging some markets are forcing them to decline volume and use PRN or contractors in spots. Medicare Advantage pricing remains contentious, and Amedisys warned it may drop contracts that do not compensate for inflation and lower utilization. Contessa is still losing about $30 million and management said 2023 losses are expected to stay roughly flat, with breakeven timing still unclear.
AI summary of the company's earnings call · Paraphrased · Not investment advice
- Free Float
- 98.0%
- Shares Outstanding
- 32.89M
- Float Shares
- 32.24M
of shares held by institutions
330 13F filers
Buy/sell ratio 0.10. Sells can include pre-scheduled 10b5-1 plan sales, not just discretionary selling.
Congressional trading
Senate and House stock disclosures for AMED, newest first.
| Member | Type | Traded | |
|---|---|---|---|
| Lisa C. McClainHouse · MI09 | Sell | Aug 18, 25 | Filing → |
| Lisa C. McClainHouse · MI09 | Buy | Jun 9, 25 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 14, 23 | Filing → |
| Ro KhannaHouse · CA17 | Sell | Mar 24, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Feb 10, 23 | Filing → |
| Ro KhannaHouse · CA17 | Buy | Jan 11, 23 | Filing → |
| Greg GianforteHouse · MT00 | Sell | Oct 13, 20 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Apr 16, 19 | Filing → |
| Donna ShalalaHouse · FL27 | Sell | Jun 24, 19 | Filing → |
| Greg GianforteHouse · MT00 | Buy | May 30, 19 | Filing → |
Source: public STOCK Act disclosures. Filed weeks after the trade — a lagging signal, not a real-time one.
Top institutional holders
Largest 13F positions, with quarter-over-quarter change.
| Holder | Shares | Δ Quarter |
|---|---|---|
| Eisler Capital (Uk) Ltd. | 73.79K | ▲ 73.79K |
| Nuveen Asset Management, LLC | 58.48K | ▼ 13.22K |
| Cigogne Management SA | 29.65K | ▲ 29.65K |
| Flow State Investments, L.P. | 17.00K | ▼ 76.13K |
| Sabal Trust Co | 6.00K | 0 |
| Lindbrook Capital, LLC | 904 | ▲ 647 |
| First Horizon Advisors, Inc. | 4 | 0 |
| Parkworth Wealth Management, Inc. | 4 | ▲ 3 |
Held by 16 ETFs
Biggest fund positions in AMED by dollar value.
Recent insider transactions
Who's buying, who's selling, and how much.
| Date | Insider | Type | Shares |
|---|---|---|---|
| Aug 14, 25 | Coye Molly Joel | sell | 8,818 |
| Aug 14, 25 | Klapstein Julie D | sell | 16,031 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 621 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 80,602 |
| Aug 14, 25 | Kusserow Paul B. K. | sell | 439,124 |
| Aug 14, 25 | Rideout Jeffrey A | sell | 9,335 |
| Aug 14, 25 | Muscato Nick | sell | 3,067 |
| Aug 14, 25 | Muscato Nick | other | 3,468 |
| Aug 14, 25 | Muscato Nick | sell | 272 |
| Aug 14, 25 | Muscato Nick | sell | 2,040 |
A “Sell” may be a pre-scheduled 10b5-1 plan sale rather than a discretionary decision — read insider selling with that in mind.
Our AMED coverage
Recent articles, reports, and earnings notes.
No research on AMED yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate AMED report →Joel Greenblatt's Strategic Moves: A Closer Look at SPDR S&P 500 ETF Trust
gurufocus.com · Nov 14
Twilio Set to Join S&P MidCap 400
prnewswire.com · Aug 14
Amedisys: Thoughts On UnitedHealth Merger, Plus Underlying Factors
seekingalpha.com · Aug 3
Amedisys (AMED) is a Top-Ranked Value Stock: Should You Buy?
zacks.com · Aug 1
Amedisys (AMED) Q2 Revenue Tops 5%
fool.com · Jul 30
Here's What Key Metrics Tell Us About Amedisys (AMED) Q2 Earnings
zacks.com · Jul 29
Amedisys (AMED) Beats Q2 Earnings and Revenue Estimates
zacks.com · Jul 29
Amedisys Reports Second Quarter 2025 Financial Results
globenewswire.com · Jul 29
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.